

GW PHARMACEUTICALS PLC

FORM 6-K (Report of Foreign Issuer)

Filed 11/03/17 for the Period Ending 11/03/17

Telephone	44 1223 266800
CIK	0001351288
Symbol	GWPH
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Medical Research
Sector	Healthcare

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934

For the Month of November, 2017

Commission File Number: 001-35892

GW PHARMACEUTICALS PLC

(Translation of registrant's name into English)

Sovereign House
Vision Park
Histon
Cambridge CB24 9BZ
United Kingdom
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes

No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes

No

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

On November 1, 2017, Dr. Geoffrey Guy, Chairman of GW Pharmaceuticals plc (the “Company”) and Justin Gover, the Company’s Chief Executive Officer sold American Depositary Shares under their respective Rule 10b5-1 plans. Details of the sales (“Transaction Details”) are set forth in Exhibit 99.1 hereto and are incorporated by reference herein. The information contained in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing.

Exhibits

[99.1 Transaction Details.](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GW Pharmaceuticals plc

By: /s/ Adam George

Name: Adam George

Title: Company Secretary

Date: November 3, 2017

**Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them**

1.	Details of the person discharging managerial responsibilities / person closely associated	
a.	Name	Justin Gover
2.	Reason for the notification	
a.	Position/status	Chief Executive Officer
b.	Initial notification /Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a.	Name	GW Pharmaceuticals PLC
b.	LEI	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a.	Description of the Financial instrument, type of instrument Identification code	American Depositary Shares ISIN: 36197T1034
b.	Nature of the transaction	Exercise of Long Term Incentive Plan options and sale of resulting American Depositary Shares an accordance with 10b5.1 plan dated 30 August 2017
c.	Price(s) and volume(s)	Price(s) \$107.89 Volume(s) 889 ADS's sold
d.	Aggregated information • <i>Aggregated volume</i> • <i>Price</i>	n/a
e.	Date of the transaction	<i>November 1, 2017</i>
f.	Place of the transaction	Nasdaq, New York

1.	Details of the person discharging managerial responsibilities / person closely associated	
a.	Name	Dr Geoffrey Guy
2.	Reason for the notification	
a.	Position/status	Chairman
b.	Initial notification /Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a.	Name	GW Pharmaceuticals PLC
b.	LEI	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a.	Description of the Financial instrument, type of instrument Identification code	American Depositary Shares ISIN: 36197T1034
b.	Nature of the transaction	Exercise of Long Term Incentive Plan options and sale of resulting American Depositary Shares an accordance with 10b5.1 plan dated 2 October 2017
c.	Price(s) and volume(s)	Price(s) \$109.53 Volume(s) 10,671 ADS's sold
d.	Aggregated information • <i>Aggregated volume</i> • <i>Price</i>	n/a
e.	Date of the transaction	<i>November 1, 2017</i>
f.	Place of the transaction	Nasdaq, New York